Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Patients And Methods: 68Ga-DOTA-FAPI-04 PET/CT was performed on a cohort of 21 patients with known SAPHO syndrome. All patients underwent 68Ga-DOTA-FAPI-04 and 18F-FDG PET/CT on 2 consecutive days. The positive rates of the PET/CT scans at the sites of the osteoarticular symptom, the uptake values, and agreement with clinical osteoarticular symptom were compared.
Results: A total of 38 sites of involvement were detected. 18F-FDG PET/CT revealed 28 lesions. In contrast, 68Ga-DOTA-FAPI-04 PET/CT detected not only all lesions shown on 18F-FDG PET/CT but additional 10 lesions. 68Ga-DOTA-FAPI-04 scan also demonstrated significantly higher uptake and target-to-background ratio than 18F-FDG studies in the skeletal involvements. The agreement between 68Ga-DOTA-FAPI-04-positive lesions and current osteoarticular lesions was substantial (κ = 0.79, P < 0.001), whereas 18F-FDG had low to moderate agreement with clinical symptoms (κ = 0.52, P < 0.001).
Conclusions: 68Ga-DOTA-FAPI-04 has potential as a promising imaging agent for the evaluation of SAPHO syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000004724 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative Evaluation of Response in Diffuse Large B-cell Lymphoma Using Ga-Pentixafor PET/CT and F-FDG PET/CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive type of non-Hodgkin lymphoma. Accurate evaluation of treatment response is essential for effective management. This case report discusses the potential role of ⁶⁸Ga-Pentixafor positron emission tomography (PET)/computed tomography (CT) in comparison to F-fluorodeoxyglucose PET/CT for assessing treatment response in a patient with DLBCL.
View Article and Find Full Text PDFF FDG PET/CT in a Rare Case of Erdheim-Chester Disease with Extensive Cutaneous and Skeletal Involvement.
Indian J Nucl Med
August 2025
Department of Haematology and Haemato-Oncology, Aster Medcity, Kochi, Kerala, India.
Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans cell histiocytosis with multiple organ involvement. Being a rare disease with variable clinical manifestations, it is often difficult to diagnose. F-2-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a vital role in assessing disease extent and severity, diagnosis, treatment response and is a potential biomarker for BRAF mutation.
View Article and Find Full Text PDFRare Pituitary Metastasis from Adenocarcinoma of Right Lung in F FDG PET/CT.
Indian J Nucl Med
August 2025
Department of Nuclear Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Lung cancer is the leading cause of cancer and cancer-related deaths, and India ranks the fourth highest country. Lung cancer is a highly aggressive malignancy with a tendency for rapid progression, making early detection and prompt treatment essential for improving patient outcomes. Lung cancer can spread locally into surrounding tissue as well as travel through lymphatics to other parts of the body, most often to bone, brain, liver, and adrenal glands.
View Article and Find Full Text PDFRecent Development of CXCR4-Targeted Nuclear Medicine Research in Adrenocortical Tumors.
Mini Rev Med Chem
September 2025
Department of PET/CT Diagnostic Imaging, Tianjin Medical University General Hospital, Tianjin 300052, China.
The diagnosis of adrenocortical tumors remains clinically challenging due to overlapping morphological and functional features between benign, malignant, and hormonally active lesions. Malignant and functional tumors are frequently associated with poor prognosis. Traditional morphological imaging methods, such as CT and MRI, cannot reliably distinguish lesion types.
View Article and Find Full Text PDFF-FDG Versus Tissue Factor-Targeted PET/CT in Longitudinal Evaluation of the Formation of DEN-Induced Rat Hepatocellular Carcinoma.
Mol Pharm
September 2025
Department of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Tissue factor (TF) has emerged as a promising target for the diagnosis and treatment of hepatocellular carcinoma (HCC). However, there is limited data available on TF-related PET imaging for longitudinal monitoring of the pathophysiological changes during HCC formation. Herein, we aimed to explore the TF-expression feature and compare a novel TF-targeted PET probe with F-FDG through longitudinal imaging in diethylnitrosamine (DEN)-induced rat HCC.
View Article and Find Full Text PDF